BACKGROUND: Left ventricular assist system technologies are currently being developed as effective alternatives to cardiac transplantation. In this study, in vivo testing of the Arrow International CorAide left ventricular assist system was conducted to determine its preclinical readiness based on demonstrated system performance and biocompatibility. METHODS: Arrow International CorAide blood pump assemblies were implanted in 7 calves for 1-month (n = 4) and 3-month (n = 3) durations without the use of chronic anticoagulation therapy. Hemodynamic performance, physiologic pump control, end-organ function, and device-related adverse events were evaluated during the studies and at autopsy. RESULTS: Hemodynamics were stable in all cases with a mean pump flow of 4.1 +/- 0.8 L/min and a mean arterial pressure of 101 +/- 4 mm Hg. In all calves, renal and hepatic function remained normal with no incidence of hemolysis, infection, bleeding, or embolism. The CorAide physiologic control algorithm demonstrated appropriate pump speed and flow adjustments in response to physiologically induced inputs, and the system's external electronic components demonstrated no hardware or software malfunction. All 7 cases were sacrificed electively. Autopsy revealed no sign of end-organ disease on gross and histologic examinations, and no device failure, malfunction, or mechanical wear of the pump blood-bearing surfaces was found. CONCLUSIONS: The Arrow CorAide left ventricular assist system demonstrated effective pump performance and good biocompatibility with no incidence of device-related adverse events. This system has completed its preclinical readiness testing and is approved for clinical trials in Europe in 2003.
BACKGROUND: Left ventricular assist system technologies are currently being developed as effective alternatives to cardiac transplantation. In this study, in vivo testing of the Arrow International CorAide left ventricular assist system was conducted to determine its preclinical readiness based on demonstrated system performance and biocompatibility. METHODS: Arrow International CorAide blood pump assemblies were implanted in 7 calves for 1-month (n = 4) and 3-month (n = 3) durations without the use of chronic anticoagulation therapy. Hemodynamic performance, physiologic pump control, end-organ function, and device-related adverse events were evaluated during the studies and at autopsy. RESULTS: Hemodynamics were stable in all cases with a mean pump flow of 4.1 +/- 0.8 L/min and a mean arterial pressure of 101 +/- 4 mm Hg. In all calves, renal and hepatic function remained normal with no incidence of hemolysis, infection, bleeding, or embolism. The CorAide physiologic control algorithm demonstrated appropriate pump speed and flow adjustments in response to physiologically induced inputs, and the system's external electronic components demonstrated no hardware or software malfunction. All 7 cases were sacrificed electively. Autopsy revealed no sign of end-organ disease on gross and histologic examinations, and no device failure, malfunction, or mechanical wear of the pump blood-bearing surfaces was found. CONCLUSIONS: The Arrow CorAide left ventricular assist system demonstrated effective pump performance and good biocompatibility with no incidence of device-related adverse events. This system has completed its preclinical readiness testing and is approved for clinical trials in Europe in 2003.
Authors: Yoshio Ootaki; Keiji Kamohara; Masatoshi Akiyama; Firas Zahr; Michael W Kopcak; Raymond Dessoffy; Alex Massiello; David Horvath; Ji-Feng Chen; Stephen Benefit; Leonard A R Golding; Kiyotaka Fukamachi Journal: ASAIO J Date: 2005 Nov-Dec Impact factor: 2.872
Authors: Kiyotaka Fukamachi; David J Horvath; Alex L Massiello; Yoshio Ootaki; Keiji Kamohara; Masatoshi Akiyama; Firas Zahr; Michael W Kopcak; Raymond Dessoffy; Ji-Feng Chen; Stephen Benefit; Leonard A R Golding Journal: ASAIO J Date: 2005 Nov-Dec Impact factor: 2.872
Authors: Akira Shiose; Kathleen Nowak; David J Horvath; Alex L Massiello; Leonard A R Golding; Kiyotaka Fukamachi Journal: ASAIO J Date: 2010 Sep-Oct Impact factor: 2.872
Authors: Kiyotaka Fukamachi; David J Horvath; Alex L Massiello; Hideyuki Fumoto; Tetsuya Horai; Santosh Rao; Leonard A R Golding Journal: J Heart Lung Transplant Date: 2009-09-26 Impact factor: 10.247